Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.54
+0.32 (2.62%)
Nov 22, 2024, 4:00 PM EST - Market closed
Cullinan Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Cash & Equivalents | 102.09 | 98.43 | 156.15 | 59.77 | 168.2 | 63.25 | Upgrade
|
| Short-Term Investments | 475.99 | 368.63 | 311.14 | 230.69 | 42.01 | 35.38 | Upgrade
|
| Cash & Short-Term Investments | 578.08 | 467.07 | 467.29 | 290.47 | 210.21 | 98.63 | Upgrade
|
| Cash Growth | 23.94% | -0.05% | 60.88% | 38.18% | 113.13% | 191.53% | Upgrade
|
| Prepaid Expenses | 13.96 | 13.12 | 7.18 | 6.1 | 2.07 | 1.46 | Upgrade
|
| Total Current Assets | 592.04 | 480.19 | 474.47 | 296.56 | 212.28 | 100.09 | Upgrade
|
| Property, Plant & Equipment | 2.78 | 3.53 | 5.3 | 0.08 | 0.13 | 0.18 | Upgrade
|
| Long-Term Investments | 57.98 | - | 80.88 | 140.4 | - | - | Upgrade
|
| Other Long-Term Assets | 0.46 | 0.46 | 0.46 | 0.15 | 2.3 | 0.19 | Upgrade
|
| Total Assets | 653.25 | 484.18 | 561.12 | 437.19 | 214.71 | 100.46 | Upgrade
|
| Accounts Payable | 2.12 | 2.49 | 2.66 | 3.17 | 9.68 | 0.93 | Upgrade
|
| Accrued Expenses | 19.12 | 23.29 | 12 | 7.6 | 4.64 | 1.56 | Upgrade
|
| Short-Term Debt | - | - | 0.18 | - | - | - | Upgrade
|
| Current Portion of Leases | 1.26 | 1.44 | 1.42 | - | - | - | Upgrade
|
| Current Income Taxes Payable | - | - | 4.28 | - | - | - | Upgrade
|
| Other Current Liabilities | 1.71 | 0.91 | 1.96 | 0.97 | - | 0.03 | Upgrade
|
| Total Current Liabilities | 24.2 | 28.14 | 22.5 | 11.75 | 14.32 | 2.52 | Upgrade
|
| Long-Term Leases | 1.19 | 2.15 | 3.59 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0.07 | 0.07 | 0.07 | Upgrade
|
| Total Liabilities | 25.39 | 30.29 | 26.09 | 11.81 | 14.39 | 2.6 | Upgrade
|
| Common Stock | 0.01 | 0 | 0.01 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 947.48 | 654.69 | 585.32 | 584.71 | 292.35 | 0.77 | Upgrade
|
| Retained Earnings | -320.59 | -200.86 | -47.7 | -158.91 | -93.34 | -41.54 | Upgrade
|
| Comprehensive Income & Other | 0.97 | -0.13 | -2.6 | -0.84 | -0 | -0 | Upgrade
|
| Total Common Equity | 627.86 | 453.7 | 535.03 | 424.97 | 199.01 | -40.77 | Upgrade
|
| Minority Interest | - | 0.19 | - | 0.4 | 1.3 | 0.86 | Upgrade
|
| Shareholders' Equity | 627.86 | 453.9 | 535.03 | 425.37 | 200.31 | 97.87 | Upgrade
|
| Total Liabilities & Equity | 653.25 | 484.18 | 561.12 | 437.19 | 214.71 | 100.46 | Upgrade
|
| Total Debt | 2.45 | 3.59 | 5.19 | - | - | - | Upgrade
|
| Net Cash (Debt) | 575.63 | 463.48 | 462.1 | 290.47 | 210.21 | 98.63 | Upgrade
|
| Net Cash Growth | 25.00% | 0.30% | 59.09% | 38.18% | 113.13% | 191.53% | Upgrade
|
| Net Cash Per Share | 11.55 | 11.15 | 9.91 | 6.74 | 10.57 | 108.52 | Upgrade
|
| Filing Date Shares Outstanding | 58.23 | 43.07 | 39.33 | 44.61 | 43.52 | 1.69 | Upgrade
|
| Total Common Shares Outstanding | 58.14 | 42.9 | 45.8 | 44.29 | 2.02 | 1.69 | Upgrade
|
| Working Capital | 567.84 | 452.05 | 451.97 | 284.82 | 197.96 | 97.57 | Upgrade
|
| Book Value Per Share | 10.80 | 10.58 | 11.68 | 9.59 | 98.36 | -24.12 | Upgrade
|
| Tangible Book Value | 627.86 | 453.7 | 535.03 | 424.97 | 199.01 | -40.77 | Upgrade
|
| Tangible Book Value Per Share | 10.80 | 10.58 | 11.68 | 9.59 | 98.36 | -24.12 | Upgrade
|
| Machinery | - | 0.77 | 0.68 | 0.2 | 0.2 | 0.19 | Upgrade
|
| Leasehold Improvements | - | 0.58 | 0.63 | 0.11 | 0.11 | 0.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.